US-India Trade Agreement Nears Final Sign-off

The deal is effectively ready, with officials currently holding the finalized paperwork. The delay stems from Washington’s pending Section 301 investigations—a statutory review process targeting perceived unfair trade practices that permits the U.S. to levy retaliatory tariffs. One broad probe encompassing 60 nations is expected to wrap up within the next two weeks, potentially clearing the path for the India agreement and similar arrangements elsewhere.

Economic cooperation between the two nations aims to lower barriers and broaden market access. However, the broader trade environment remains complex. Washington has proposed tariffs reaching 12.5% on various countries, including India, citing concerns over goods produced with forced labor. Simultaneously, the Indian pharmaceutical sector faces uncertainty due to new U.S. drug tariff policies. With the United States accounting for $9.7 billion of India’s $25.8 billion in pharmaceutical exports, any shift in import duties could significantly impact the industry’s export footprint.